m+Medelevator.RU
← Поиск публикаций
Nanomedicine (London, England) · 2025

Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Liaqat Rabia, Rasool Fatima, Noreen Sobia, Rai Nadia, Naseem Ayesha, Shoaib Muhammad Hamza, Mahmood Hassan, Ashraf Muhammad Azeem

Аннотация

AIMS: This study aimed to fabricate, characterize, and perform molecular docking of furosemide-loaded nanosponges (NSs) using the emulsion solvent diffusion method.

MATERIAL AND METHODS: Sustained-release NS formulations of furosemide were developed using ethylcellulose, polyvinyl alcohol (PVA), and dichloromethane (DCM) via the emulsion solvent diffusion technique. The formulations were evaluated for production yield, actual drug content, entrapment efficiency, drug-polymer compatibility, surface morphology, docking study, and in vitro drug release.

RESULTS: SEM images displayed the nanosized, spherical, porous, and spongy texture of furosemide NS. Fourier-transform infrared spectroscopy (FTIR) spectra showed no drug-polymer incompatibility. Powder X-ray diffraction (PXRD) analysis indicated an amorphous state of furosemide, while differential scanning calorimetry (DSC) suggested drug-polymer complexation. In vitro studies demonstrated sustained drug release for up to 10 h. Molecular docking supported stable interactions between furosemide and polymers. Molecular dynamics (MD) simulations further revealed adequate hydrogen bonding and diffusion behavior, confirming polymer composition-dependent release and structural stability.

CONCLUSION: These findings indicate that furosemide-loaded NSs are a promising sustained-release delivery system capable of reducing dosing frequency and enhancing patient compliance.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты